Insider Buy/Sell Details for the Biotechnology Industry — January 2026
Ratio0.1:1
Daily Buy & Sell Volume
Transactions (1179)
NewAmsterdam Pharma Co N.V. (NAMS)
Kastelein Johannes Jacob Pieter — Director
Shares
6,000
Price
$33.25
Total Value
$199.50K
Shares Held After
73,481
% of Holdings
7.5%
NewAmsterdam Pharma Co N.V. (NAMS)
Kooij Louise Frederika — Chief Accounting Officer
Shares
2,647
Price
$33.25
Total Value
$88.01K
Shares Held After
12,353
% of Holdings
17.6%
NewAmsterdam Pharma Co N.V. (NAMS)
Somaiya Mayur Ian — Chief Financial Officer
Shares
5,118
Price
$33.25
Total Value
$170.17K
Shares Held After
32,882
% of Holdings
13.5%
PharmaCyte Biotech, Inc. (PMCB)
Silverman Joshua — Director
Shares
30,000
Price
$0.78
Total Value
$23.49K
Shares Held After
346,250
% of Holdings
8.7%
Arcutis Biotherapeutics, Inc. (ARQT)
Burnett Patrick — Reporting Person's Title: Executive Vice President and Chief Medical Officer
Shares
2,490
Price
$28.98
Total Value
$72.17K
Shares Held After
94,120
% of Holdings
2.6%
PharmaCyte Biotech, Inc. (PMCB)
SCHECHTER JONATHAN — Director
Shares
20,000
Price
$0.78
Total Value
$15.55K
Shares Held After
152,500
% of Holdings
13.1%
Nuvalent, Inc. (NUVL)
Noci Darlene — Chief Development Officer
Shares
871
Price
$96.06
Total Value
$83.67K
Shares Held After
47,163
% of Holdings
1.8%
Clene Inc. (CLNN)
Ugwumba Chidozie — 10% Owner
Shares
5,869
Price
$5.87
Total Value
$34.45K
Shares Held After
760,611
% of Holdings
0.8%
Nuvalent, Inc. (NUVL)
Porter James Richard — Director
Shares
3,679
Price
$96.06
Total Value
$353.40K
Shares Held After
302,383
% of Holdings
1.2%
Nuvalent, Inc. (NUVL)
Turner Christopher Durant — Chief Medical Officer
Shares
871
Price
$96.06
Total Value
$83.67K
Shares Held After
61,676
% of Holdings
1.4%
Nuvalent, Inc. (NUVL)
Pelish Henry E. — Chief Scientific Officer
Shares
513
Price
$96.06
Total Value
$49.28K
Shares Held After
70,535
% of Holdings
0.7%
Werewolf Therapeutics, Inc. (HOWL)
EVNIN LUKE — Director
Shares
18,378
Price
$0.64
Total Value
$11.76K
Shares Held After
2,453,919
% of Holdings
0.7%
Nuvalent, Inc. (NUVL)
Miller Deborah Ann — Chief Legal Officer
Shares
897
Price
$96.06
Total Value
$86.17K
Shares Held After
48,189
% of Holdings
1.8%
Nuvalent, Inc. (NUVL)
Balcom Alexandra — Chief Financial Officer
Shares
871
Price
$96.06
Total Value
$83.67K
Shares Held After
88,279
% of Holdings
1.0%
Climb Bio, Inc. (CLYM)
RA CAPITAL MANAGEMENT, L.P. — Director
Shares
7,111
Price
$3.50
Total Value
$24.89K
Shares Held After
3,403,429
% of Holdings
0.2%
Intellia Therapeutics, Inc. (NTLA)
BASTA JAMES — EVP, General Counsel
Shares
10,397
Price
$9.21
Total Value
$95.76K
Shares Held After
101,528
% of Holdings
9.3%
Intellia Therapeutics, Inc. (NTLA)
Lebwohl David — EVP, Chief Medical Officer
Shares
11,903
Price
$9.21
Total Value
$109.63K
Shares Held After
121,249
% of Holdings
8.9%
Intellia Therapeutics, Inc. (NTLA)
LEONARD JOHN M — Director
Shares
34,146
Price
$9.21
Total Value
$314.48K
Shares Held After
1,013,339
% of Holdings
3.3%
Travere Therapeutics, Inc. (TVTX)
Inrig Jula — CHIEF MEDICAL OFFICER
Shares
2,031
Price
$40.18
Total Value
$81.61K
Shares Held After
86,756
% of Holdings
2.3%
Arcus Biosciences, Inc. (RCUS)
Jaen Juan C. — President
Shares
29,670
Price
$21.34
Total Value
$633.16K
Shares Held After
924,393
% of Holdings
3.1%
Intellia Therapeutics, Inc. (NTLA)
Cohen Fred E — Director
Shares
150,000
Price
$9.35
Total Value
$1.40M
Shares Held After
207,453
% of Holdings
72.3%
Intellia Therapeutics, Inc. (NTLA)
Clark Eliana — EVP, Chief Technical Officer
Shares
9,515
Price
$9.21
Total Value
$87.63K
Shares Held After
87,118
% of Holdings
9.8%
Intellia Therapeutics, Inc. (NTLA)
Dulac Edward J III — EVP, Chief Financial Officer
Shares
6,379
Price
$9.21
Total Value
$58.75K
Shares Held After
99,683
% of Holdings
6.0%
Intellia Therapeutics, Inc. (NTLA)
Dube Michael P — VP, Chief Accounting Officer
Shares
2,989
Price
$9.21
Total Value
$27.53K
Shares Held After
52,277
% of Holdings
5.4%
Intellia Therapeutics, Inc. (NTLA)
Schultes Birgit C — EVP, Chief Scientific Officer
Shares
8,508
Price
$9.21
Total Value
$78.36K
Shares Held After
98,533
% of Holdings
7.9%
INCYTE CORP (INCY)
Stein Steven H — EVP & Chief Medical Officer
Shares
15,634
Price
$101.70
Total Value
$1.59M
Shares Held After
34,203
% of Holdings
31.4%
Actuate Therapeutics Inc (ACTU)
THOMSON TODD S — Director
Shares
280,000
Price
$5.80
Total Value
$1.62M
Shares Held After
904,795
% of Holdings
23.6%
HALOZYME THERAPEUTICS, INC. (HALO)
Connaughton Bernadette — Director
Shares
2,000
Price
$70.25
Total Value
$140.50K
Shares Held After
40,123
% of Holdings
4.7%
Xeris Biopharma Holdings, Inc. (XERS)
Shannon John Patrick Jr — Director
Shares
24,907
Price
$7.08
Total Value
$176.26K
Shares Held After
2,705,346
% of Holdings
0.9%
UNITED THERAPEUTICS Corp (UTHR)
MALCOLM JAN — Director
Shares
50
Price
$495.01
Total Value
$24.75K
Shares Held After
370
% of Holdings
11.9%
Contineum Therapeutics, Inc. (CTNM)
Lorrain Daniel S. — Chief Scientific Officer
Shares
3,670
Price
$10.35
Total Value
$37.98K
Shares Held After
160,722
% of Holdings
2.2%
Apellis Pharmaceuticals, Inc. (APLS)
Baumal Caroline — Chief Medical Officer
Shares
3,020
Price
$25.53
Total Value
$77.10K
Shares Held After
91,206
% of Holdings
3.2%
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Hamilton James C — Chief Medical Officer
Shares
4,625
Price
$61.24
Total Value
$283.24K
Shares Held After
207,497
% of Holdings
2.2%
Ultragenyx Pharmaceutical Inc. (RARE)
Horn Howard — Chief Financial Officer
Shares
3,150
Price
$22.84
Total Value
$71.95K
Shares Held After
91,996
% of Holdings
3.3%
Fennec Pharmaceuticals Inc. (FENC)
Raykov Rosty — Director
Shares
10,312
Price
$7.60
Total Value
$78.37K
Shares Held After
88,020
% of Holdings
10.5%
Xilio Therapeutics, Inc. (XLO)
Frankenfield Christopher James — Chief Financial Officer
Shares
7,030
Price
$0.64
Total Value
$4.52K
Shares Held After
24,766
% of Holdings
22.1%
Vir Biotechnology, Inc. (VIR)
SATO VICKI L — Director
Shares
22,000
Price
$5.93
Total Value
$130.38K
Shares Held After
1,166,391
% of Holdings
1.9%
Nuvalent, Inc. (NUVL)
Miller Deborah Ann — Chief Legal Officer
Shares
540
Price
$101.47
Total Value
$54.79K
Shares Held After
49,086
% of Holdings
1.1%
Nuvalent, Inc. (NUVL)
Miller Deborah Ann — Chief Legal Officer
Shares
5,455
Price
$100.77
Total Value
$549.70K
Shares Held After
49,626
% of Holdings
9.9%
Nuvalent, Inc. (NUVL)
Miller Deborah Ann — Chief Legal Officer
Shares
4,005
Price
$100.03
Total Value
$400.62K
Shares Held After
55,081
% of Holdings
6.8%
Xilio Therapeutics, Inc. (XLO)
Brennan Kevin M. — SVP, FINANCE AND ACCOUNTING
Shares
1,826
Price
$0.64
Total Value
$1.17K
Shares Held After
6,371
% of Holdings
22.3%
UNITED THERAPEUTICS Corp (UTHR)
MAHON PAUL A — EVP & GENERAL COUNSEL
Shares
200
Price
$489.15
Total Value
$97.83K
Shares Held After
36,781
% of Holdings
0.5%
UNITED THERAPEUTICS Corp (UTHR)
MAHON PAUL A — EVP & GENERAL COUNSEL
Shares
2,181
Price
$487.76
Total Value
$1.06M
Shares Held After
36,981
% of Holdings
5.6%
UNITED THERAPEUTICS Corp (UTHR)
MAHON PAUL A — EVP & GENERAL COUNSEL
Shares
1,130
Price
$486.85
Total Value
$550.14K
Shares Held After
39,162
% of Holdings
2.8%
UNITED THERAPEUTICS Corp (UTHR)
MAHON PAUL A — EVP & GENERAL COUNSEL
Shares
1,509
Price
$485.68
Total Value
$732.89K
Shares Held After
40,292
% of Holdings
3.6%
UNITED THERAPEUTICS Corp (UTHR)
MAHON PAUL A — EVP & GENERAL COUNSEL
Shares
1,240
Price
$484.54
Total Value
$600.82K
Shares Held After
41,801
% of Holdings
2.9%
UNITED THERAPEUTICS Corp (UTHR)
MAHON PAUL A — EVP & GENERAL COUNSEL
Shares
739
Price
$483.35
Total Value
$357.20K
Shares Held After
43,041
% of Holdings
1.7%
UNITED THERAPEUTICS Corp (UTHR)
MAHON PAUL A — EVP & GENERAL COUNSEL
Shares
479
Price
$481.83
Total Value
$230.80K
Shares Held After
43,780
% of Holdings
1.1%
UNITED THERAPEUTICS Corp (UTHR)
MAHON PAUL A — EVP & GENERAL COUNSEL
Shares
822
Price
$481.26
Total Value
$395.60K
Shares Held After
44,259
% of Holdings
1.8%
Clene Inc. (CLNN)
Ugwumba Chidozie — 10% Owner
Shares
4,015
Price
$5.73
Total Value
$23.01K
Shares Held After
766,480
% of Holdings
0.5%
Showing 1051–1100 of 1179 transactions (page 22 of 24)